Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 17, 2026

Major bank drops bombshell on Fed interest-rate bets

View original at finance.yahoo.com
Major bank drops bombshell on Fed interest-rate bets After an especially bruising week of hot back-to-back inflation headlines, increasing uncertainties about the end of the Iran war’s energy shocks, and a flaccid state visit to China, the bond market’s outlook for a Fed interest-rate hike this year flexed…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The market-implied probability of a quarter-point Fed rate hike in 2026 is 50% as of May 15, up from 40% the previous day and from approximately 10% at the start of the year.

    60% confidence
  • March Core PCE (excluding food and energy) rose to 3.2% year over year, up from 2.9% in February.

    60% confidence
  • March headline PCE rose to 3.5% year over year, up from 2.8% in February, largely driven by energy costs.

    60% confidence
  • The 30-year Treasury yield topped the 5% threshold during the week of May 15, 2026.

    60% confidence
  • The FOMC will entertain rate hikes only in a world of bad choices: either allowing inflation to increase further and become entrenched, or accepting the risk that a policy adjustment could prove macroeconomically destabilizing.

    60% confidence
  • The April PCE inflation report due May 28 will remain elevated and reinforce expectations that the Fed keeps the benchmark Federal Funds Rate higher for longer.

    60% confidence
  • The Federal Open Market Committee is likely to strongly prefer a long-term hold stance to rate hikes in 2026.

    60% confidence
  • If the Fed begins hiking rates later in 2026 under new Chair Kevin Warsh, this would create downside risk to BNP Paribas's otherwise optimistic economic outlook.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com